245 related articles for article (PubMed ID: 32981302)
21. Utility of adjuvant radioactive iodine therapy after reoperation in papillary thyroid carcinoma with cervical lymph node recurrence.
Zhang Y; Zhu X; Fan Q; Huang Q; Tu Y; Jiang L; Zhang Z; Chen J
Jpn J Radiol; 2023 Oct; 41(10):1148-1156. PubMed ID: 37266825
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of postoperative radioactive iodine scans in patients who underwent prophylactic central lymph node dissection.
Laird AM; Gauger PG; Miller BS; Doherty GM
World J Surg; 2012 Jun; 36(6):1268-73. PubMed ID: 22270997
[TBL] [Abstract][Full Text] [Related]
23. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
24. Outpatient ablation treatment with two doses of 30 mCi of radioactive iodine for non-low-risk papillary thyroid cancer.
Uno A; Takeda H; Mori M; Yamamoto Y; Takenaka Y; Enomoto K; Takeda N
J Med Invest; 2023; 70(1.2):17-21. PubMed ID: 37164716
[TBL] [Abstract][Full Text] [Related]
25. Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition.
Chow SM; Yau S; Kwan CK; Poon PC; Law SC
Endocr Relat Cancer; 2006 Dec; 13(4):1159-72. PubMed ID: 17158761
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant radioactive therapy after reoperation for locoregionally recurrent papillary thyroid cancer in patients who initially underwent total thyroidectomy and high-dose remnant ablation.
Yim JH; Kim WB; Kim EY; Kim WG; Kim TY; Ryu JS; Moon DH; Sung TY; Yoon JH; Kim SC; Hong SJ; Shong YK
J Clin Endocrinol Metab; 2011 Dec; 96(12):3695-700. PubMed ID: 21976723
[TBL] [Abstract][Full Text] [Related]
27. The outcomes and prognostic factors of patients who underwent reoperation for persistent/recurrent papillary thyroid carcinoma.
Sun W; Di L; Chen L; Li D; Wu Y; Xiang J; Zhou S; Sun T
BMC Surg; 2022 Nov; 22(1):374. PubMed ID: 36324095
[TBL] [Abstract][Full Text] [Related]
28. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.
Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB
Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997
[TBL] [Abstract][Full Text] [Related]
29. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence.
Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284
[TBL] [Abstract][Full Text] [Related]
30. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.
Sohn SY; Choi JY; Jang HW; Kim HJ; Jin SM; Kim SW; Suh S; Hur KY; Kim JH; Chung JH; Kim SW
Thyroid; 2013 Jun; 23(6):741-7. PubMed ID: 23205883
[TBL] [Abstract][Full Text] [Related]
31. Is Postoperative Adjuvant Radioactive Iodine Ablation Therapy Always Necessary for Intermediate-Risk Papillary Thyroid Cancer Patients With Central Neck Metastasis?
Han K; Noh HM; Jeong HM; Lim YC
Ann Surg Oncol; 2021 Nov; 28(12):7533-7544. PubMed ID: 34043093
[TBL] [Abstract][Full Text] [Related]
32. A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol.
Lee EK; Lee YJ; Park YJ; Moon JH; Yi KH; Kim KS; Lee JH; Cho SW; Joo J; Hwangbo Y; Go S; Park DJ
Endocrinol Metab (Seoul); 2020 Sep; 35(3):571-577. PubMed ID: 32981299
[TBL] [Abstract][Full Text] [Related]
33. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
Rosário PW; Calsolari MR
Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for radioactive iodine-avid metastatic lymph nodes on post I-131 ablation SPECT/CT in low- or intermediate-risk groups of papillary thyroid cancer.
Lee CH; Jung JH; Son SH; Hong CM; Jeong JH; Jeong SY; Lee SW; Lee J; Ahn BC
PLoS One; 2018; 13(8):e0202644. PubMed ID: 30118516
[TBL] [Abstract][Full Text] [Related]
35. Propensity score matching analysis of adjuvant external-beam radiotherapy for the treatment of papillary thyroid carcinoma with other organ invasions.
Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T
Endocrine; 2023 Jun; 80(3):589-599. PubMed ID: 36600104
[TBL] [Abstract][Full Text] [Related]
36. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
37. Level V Metastasis, a Novel Predicative Factor for Recurrence in N1b Papillary Thyroid Carcinoma.
Wu Y; Li J; Wu X; Dai L
Curr Pharm Des; 2018; 24(5):559-563. PubMed ID: 28990528
[TBL] [Abstract][Full Text] [Related]
38. Effect of Radioactive Iodine Therapy on Cancer-Specific Survival of Papillary Thyroid Cancer Tall Cell Variant.
Dai P; Zhao W; Zheng X; Luo H; Wang X
J Clin Endocrinol Metab; 2024 Feb; 109(3):e1260-e1266. PubMed ID: 37804527
[TBL] [Abstract][Full Text] [Related]
39. Papillary thyroid carcinoma with exclusive involvement of a functioning recurrent laryngeal nerve may be treated with shaving technique.
Lee HS; Kim SW; Park T; Nam GY; Hong JC; Lee KD
World J Surg; 2015 Apr; 39(4):969-74. PubMed ID: 25446493
[TBL] [Abstract][Full Text] [Related]
40. Natural history, predictive factors of apparent disease (structural or biochemical) and spontaneous excellent response in patients with papillary thyroid carcinoma and indeterminate response to initial therapy with radioiodine.
Rosario PW; Mourão GF
Endocrine; 2022 Jun; 76(3):671-676. PubMed ID: 35347578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
